Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022

Key Takeaway: SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022,

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a corporate update.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. An archived replay of the webcast will be available on the Company’s website.
Audio Conference Call:
U.S. Dial-in Number: (800) 715-9871
International Dial-in Number: (646) 307-1963
Conference ID: 4032732
About CytomX Therapeutics, Inc.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
VP, Investor Relations & Corp. Communications
Investor and Media Contact:
Stern Investor Relations
Last updated: Jul 28, 2022